This text is a result of machine translation.
Declaration of the first affordable rental housing REITs
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Yingkang life: it is expected to lose 300 million yuan to 370 million yuan in 2021
The coal sector fell sharply at the opening, and Shanghai Energy fell by the limit
Alphamab Licenses Cancer Drug to Pathos AI in Deal Worth More Than US$2.2 Billion
Alphamab Oncology (康宁杰瑞生物制药) has licensed the overseas rights to its experimental cancer drug JSKN016 to US-based Pathos AI in a deal potentially worth more than US$2.2 billion, marking another major overseas licensing agreement for China’s rapidly expanding innovative-drug sector.
Aug 06, 2026 05:41 PM
Beijing Pilots The DRG External Payment Mode
DRG refers to the diagnosis-related group used to classify the patient and set up a system to ensure the care provided is necessary. The National Healthcare Security Administration will pay the hospital a predetermined amount according to a patient’s DRG.
Jul 16, 2022 12:12 AM
New Normal, New Policies: A Focus on Healthcare in Two Sessions
The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.
Jun 03, 2020 03:06 PM
Daodaoquan: Chongqing subsidiary plans to apply to the bank for a credit line of 160 million yuan
Beyond Capital: Why Europe Needs Industrial Partners, Not Just Investors
Aug 04, 2026 11:21 AM
A Small Aircraft, a Bigger Bet: How China's Worthy Aero Plans to Scale Up
Jul 31, 2026 02:44 PM